Abstract 5550: Corilagin, an Anti-Tumor Herb Medicine, Sensitizes Paclitaxel and Carboplatin by Primarily Inhibiting Glycolysis Pathways in Epithelial Ovarian Cancer

Luoqi Jia,Hongyan Jin,Minzhi Lv,Naiqing Zhao,Shaosong Liu,Zhizhong Zheng,Yiling Lu,Yanling Ming,Yinhua Yu
DOI: https://doi.org/10.1158/1538-7445.am2015-5550
IF: 11.2
2015-01-01
Cancer Research
Abstract:We have identified that Corilagin is a major anti-tumor active component extracted from a well-known hepatoprotective and antiviral medicinal herb, Phyllanthus niruri L. Our previous works found that Corilagin inhibited the growth of ovarian cancer cells via TGF-β/AKT/ERK signaling pathways. Recently, we have examined if Corilagin could enhance the sensitivity of chemotherapy in ovarian cancer cells. Different concentration of Corilagin were used in combination assays with paclitaxel and carboplatin in ovarian cancer cell lines SKOv3ip, Hey and HO-8910PM. Corilagin distinctly increased inhibition effects of paclitaxel and carboplatin (p Citation Format: Luoqi Jia, Hongyan Jin, Minzhi Lv, Naiqing Zhao, Shaosong Liu, Zhizhong Zheng, Yiling Lu, Yanling Ming, Yinhua Yu. Corilagin, an anti-tumor herb medicine, sensitizes paclitaxel and carboplatin by primarily inhibiting glycolysis pathways in epithelial ovarian cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5550. doi:10.1158/1538-7445.AM2015-5550
What problem does this paper attempt to address?